Table 2 Overview of PDQ-39 total scores for pramipexole and placebo
Baseline, mean (SD/IQR) | Change from baseline, baseline–follow-up (SE/95% CI) | Mean difference between treatment groups, PPX vs PBO (SE) | |||
|---|---|---|---|---|---|
PPX | PBO | PPX | PBO | ||
Schapira, 2013a [27] | 12.5 (10.1) | 12.2 (9.9) | –0.1 (7.3) | 2.5 (9.0) | –2.60 (0.74) |
Poewe, 2011b,c [22] | ER: 30.8 (21.5) IR: 29.8 (20.8) | 28.6 (22.8) | ER: –3.8 (–5.9 to –1.8) IR: –6.5 (–8.6 to –4.5) | –1.5 (–4.4 to 1.5) | –3.68 (2.19) |
Schapira, 2011c [23] | ER: 53.1 (27.6) IR: 53.3 (26.9) | 51.1 (28.3) | ER: –9.1 (1.9) IR: –13.1 (1.8) | –6.2 (1.8) | –5.0 (3.12) |
Sampaio, 2011 [26] | 18.9 (13.8) | 17.4 (14.9) | –0.9 (0.9) | 0.1 (0.9) | –1.0 (1.18) |
Kieburtz, 2011c,d [24] | 0.5 mg bid: 12.2 (8.9) 0.75 mg bid: 14.4 (9.1) 0.5 mg tid: 12.0 (8.3) | 12.8 (11.5) | NA | NA | –1.72 (1.15) |
Poewe, 2007b [25] | 32.9 (14.02) | 34.8 (13.91) | –5.1 (10.1) | –1.3 (9.4) | –3.80 (1.18) |